Atrys Health Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Isabel Lozano Fernandez

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	1.6yrs

Mises à jour récentes de la gestion

Recent updates

Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate

Dec 11

PDG

Isabel Lozano Fernandez

no data

Titularisation

Ms. Isabel Lozano Fernandez serves as Chief Executive Officer and Executive Director at Atrys Health, S.A. Ms. Lozano Fernández served as Chief Executive Officer and Managing Director of PharmaMar, SA. Ms....

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Santiago De Torres Sanahuja	Executive Chairman	no data	pas de données	0.18% € 447.4k
Isabel Lozano Fernandez	CEO & Executive Director	no data	pas de données	0.44% € 1.1m
Antonio Baselga de la Vega	Director	no data	pas de données	pas de données
Josep Echarri Torres	Director	no data	pas de données	pas de données
Jaime Cano Fernandez	Independent Director	no data	pas de données	0.030% € 74.6k
Jaime del Barrio Seoane	Independent Director	no data	pas de données	0.030% € 74.6k
Fernando de Lorenzo Lopez	Director	no data	pas de données	pas de données
Francisco Jose Navarro	Proprietary Director	less than a year	pas de données	pas de données
Anabel Porta	Proprietary Director	2.9yrs	pas de données	pas de données
Manuel Maldonado	Proprietary Director	1.8yrs	pas de données	pas de données
Gonzalez Miriam	Independent Director	1.4yrs	pas de données	pas de données

1.6yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Le conseil d'administration de la ATRY n'est pas considéré comme expérimenté ( 1.6 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Atrys Health Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Consensus EPS estimates fall by 32%

Consensus EPS estimates upgraded to €0.094 loss

Consensus EPS estimates fall by 22%

Atrys Health, S.A.'s (BME:ATRY) 38% Share Price Surge Not Quite Adding Up

Full year 2023 earnings released: €0.60 loss per share (vs €0.34 loss in FY 2022)

Consensus EPS estimates fall by 65%

Consensus EPS estimates fall by 25%

New minor risk - Share price stability

Now 23% undervalued after recent price drop

Arraigo Midco Sl acquired a 75% stake in Professional Group Conversia, S.L.U from Atrys Health, S.A. (BME:ATRY) for €35 million.

Price target decreased by 8.4% to €7.23

First half 2023 earnings released: €0.17 loss per share (vs €0.044 loss in 1H 2022)

New minor risk - Financial position

Is Atrys Health, S.A. (BME:ATRY) Trading At A 44% Discount?

New minor risk - Share price stability

The Returns At Atrys Health (BME:ATRY) Aren't Growing

Price target decreased by 15% to €8.85

Full year 2022 earnings released: €0.34 loss per share (vs €0.46 loss in FY 2021)

Atrys Health, S.A. acquired 70% stake in Initia Research.

Atrys Health, S.A. (BME:ATRY) acquired ChileRad for €10 million.

Returns On Capital Are Showing Encouraging Signs At Atrys Health (BME:ATRY)

Less than half of directors are independent

Price target decreased to €10.46

First half 2022 earnings released: EPS: €0 (vs €0.084 loss in 1H 2021)

Juan María Riberas Mera acquired a 5.432% stake in Atrys Health, S.A. (BME:ATRY) for €28 million.

Atrys Health, S.A. (BME:ATRY) agreed to acquire Significant Impact Systems SL for €94.47 million.

Less than half of directors are independent

Full year 2021 earnings: Revenues miss analyst expectations

Now 21% undervalued after recent price drop

Atrys Health (BME:ATRY) Might Have The Makings Of A Multi-Bagger

Price target increased to €11.39

Atrys Health, S.A. (BME:ATRY) signed an agreement to acquire Genetyca.

An unknown buyer acquired 5% stake in Atrys Health, S.A. (BME:ATRY) from Inversiones Industriales Serpis S.L.

Price target raised to €10.18

Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America

Did You Miss Atrys Health's (BME:ATRY) Whopping 387% Share Price Gain?

New 90-day high: €10.20

New 90-day high: €8.90

Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate

Atrys Health, S.A. (BME:ATRY) acquired 91.7% stake in Grupo Lenitudes SGPS, SA from MCH Iberian Capital Fund III, FCR managed by MCH for €19.6 million.

New 90-day high: €7.86

Atrys Health, S.A. (BME:ATRY) acquired Instituto de Estudios Celulares y Moleulares S.A.

Atrys Health, S.A. (BME:ATRY) acquired Axismed Gestão Preventiva da Saúde S.A. from Telefónica Digital España, S.L. for BRL 14 million.

Atrys Health, S.A. announced that it has received €35.2 million in funding

PDG

Titularisation

Membres du conseil d'administration

Durée moyenne de l'emploi